Transformação farmacêutica de comprimidos de Pirimetamina para uso em neonatos

Abstract

Toxoplasmosis is a zoonosis caused by the etiologic agent T. gondii belonging to the phylum Apicomplexa, being a sporozoan that presents mammals and man as intermediate hosts and mainly the cat as the definitive host. The intermediate host can become infected by consuming water and/or food with oocysts, ingesting raw or undercooked meat containing viable cysts, transplacental transmission of tachyzoites from the mother to the fetus, organ transplantation and blood transfusion. One of the forms of infection is transplacental, which is the focus of our work. The treatment is carried out in symptomatic or non-symptomatic children since the first days of life when the mother has a confirmed diagnosis of the disease, the regimen is composed of sulfadiazine, pyrimethamine and folinic acid drugs. This work aimed to develop a liquid pharmaceutical form from pyrimethamine tablets together with the GUTE vehicle developed at the UFC's Pharmacotechnical laboratory and to carry out an accelerated stability study to evaluate the physicochemical characteristics and establish a shelf life for the developed suspension. The evaluation of this formulation was performed by characterizing the tablets, identifying the active ingredient and calibration curve and during the stability study it was verified for approximately six months pH, density and rheological behavior stipulating from the viscosity characteristics a shelf life. The formulated suspension presented an easy process, had a good viscosity aspect with easy redispersion of the particles, in the degradation studies of the tablets it demonstrated the need for care in relation to oxidative media, one of the limitations observed in the experiment was in relation to the verification of the active content in the suspension during the stability study. At the end of the experiment it was possible to establish a shelf life of 49 days, it can also be concluded that the suspension was obtained through a practical and economically feasible process and can be suggested as an alternative pharmaceutical form to be used in the hospital environment